CTOs on the Move

Lybradyn Inc

www.lybradyn.com

 
Lybradyn Inc is a Oak Brook, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.lybradyn.com
  • 125 Windsor Dr Ste 126
    Oak Brook, IL USA 60523
  • Phone: 630.575.8313

Executives

Name Title Contact Details

Similar Companies

CovX Research

CovX Research is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Proteonomix

The mission of Proteonomix, Inc. is to achieve a leadership position in life enhancement regenerative stem cell therapies, services, and products through a combination of first to market technologies, and innovative clinical trial strategies.

Solid Biosciences

Solid Biosciences (Solid) is a life science company singularly focused on solving Duchenne muscular dystrophy (Duchenne). We aim to be the center of excellence across the entire disease spectrum, serving as a catalyst to bring together those with the expertise in science, technology, disease management and care. Disease-focused and founded by a family directly impacted, our mandate is simple yet comprehensive - attack the roots of the disease and improve daily life for patients. Solid is headquartered in Cambridge, MA, USA.

Active Motif

Active Motif is a fast-growing biotechnology company that is dedicated to developing new and innovative tools and techniques that help analyze nuclear function. Our employees are our biggest asset and our corporate policy is to treat them as such. This

Federation Bio

Federation Bio is a biotechnology company pioneering a novel approach to create potent, durable and safe cell therapies. The company`s first-in-class platform combines the power of genetic engineering and synthetic consortium design to control systemic immune responses and broad metabolic functions. Federation Bio`s pipeline addresses a range of serious illnesses from metabolic disorders to metastatic cancer. The company`s lead program is in enteric hyperoxaluria, a serious renal condition that affects more than 250,000 Americans and for which there are currently no approved therapies.